Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Meaghan O’Donnell et al, adding:
“Are we overlooking what matters most to women with von Willebrand disease?
Heavy menstrual bleeding (HMB) is the most common and often the most severe bleeding symptom in women with von Willebrand disease (VWD). Yet a review of interventional VWD prophylaxis trials found that menstrual outcomes remain strikingly underrepresented in study design and reporting.
Among 10 eligible clinical trials, only 2 (20%) incorporated menstrual-related inclusion criteria, while 4 (40%) specifically excluded treated menstrual bleeding from bleed eligibility criteria. Although 80% of studies measured annualized bleeding rates, only 40% collected menstrual outcomes, highlighting a disconnect between trial endpoints and the experiences of many patients.
The authors argue that VWD trials have largely adopted outcome measures designed for hemophilia, rather than focusing on female-specific bleeding.
They call for future studies to incorporate menstrual outcomes, improve reporting of women of reproductive age, and ensure clinical trial design better reflects the needs of people living with VWD.”
Title: Menstrual outcomes are frequently overlooked in von Willebrand disease trials
Authors: Meaghan O’Donnell, Claire Kelly, Rezan Abdul Kadir, Roseline D’Oiron, Petra Elfvinge, Gaby Golan, Keith Gomez, Samantha C. Gouw, Laura Quintas, Karin P.M. van Galen, Michelle Lavin
Other posts featuring RPTH Journal on Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight
-
Aug 14, 2026, 18:20Venkata Sagi: Systemic Anticoagulation or Left Atrial Appendage Closure?